September 12, 2018 Leadership

BT Slingsby steps down from CEO, end of FY2018

Tokyo Japan (September 12, 2018) -- The Global Health Innovative Technology Fund (GHIT) announced today that BT Slingsby intends to step down from his CEO position after six years of service as founding CEO, conceptualizing the organization in 2011, operationalizing it in 2013, growing it by over three-fold by 2018, and leading its investment in Japanese product development for global health.


“Dr. Slingsby’s leadership, dedication, and passion has transformed Japan’s entire global health R&D landscape. Under his leadership, GHIT is now internationally recognized as Japan’s flagship entity for global health R&D.” said Hideo Suzuki, Ambassador, Assistant Minister for Global Issues/Director-General for Global Issues, Ministry of Foreign Affairs, Japan.


George Nakayama, Representative Director, Chairman and CEO, Daiichi Sankyo Company, Limited, and President, Japan Pharmaceutical Manufacturers Association says, “Dr. Slingsby’s entrepreneurship played pivotal role in the inception of GHIT and opened a new gateway for industry engagement in open innovation. GHIT’s creation has made it possible for Japanese companies to contribute to global health while increasing their corporate value by developing innovative life-saving medicines for the voiceless and poorest around the world.”


“Dr. Slingsby has been an unparalleled pioneer for innovative finance and partnership in global health.” noted Jeremy Farrar, Director, Wellcome Trust. “GHIT’s disruptive approach now serves as a model for similar initiatives aimed at galvanizing innovation for global health where market mechanisms are insufficient.”


“Dr. Slingsby catalyzed this breakthrough partnership between the Bill & Melinda Gates Foundation and Japan in 2013 and has effectively transformed how Japan's pharmaceutical industry, universities, and research organizations engage in global health R&D. The resulting impact has been no less than a shift in the landscape and a portfolio of potential life-saving medicines for millions in low-middle income countries,” said Trevor Mundel, President, Global Health, Bill & Melinda Gates Foundation.


BT Slingsby will remain in his CEO role until the end of March, 2019. The GHIT Fund is undertaking a global search for his successor. Under Dr. Slingsby’s leadership, GHIT’s funding partners and sponsors increased from eight to 26 impressive organizations; capital under management increased from $100 million to $350 million; and GHIT now manages a robust portfolio over 40 ongoing programs for innovative drugs, vaccines, and diagnostics.


“Leading GHIT through its launch, operationalization, and scale up - with such exceptional partners and a truly remarkable management team - has been the honor of my life.” says BT Slingsby. “GHIT was conceived with a mentor of mine, launched with the support of key persons in industry, government and at the Foundation, and grew with the counsel of our Council, Board, Selection Committee, and Advisory Panel. It is true partnership at its best and I believe the stellar leadership team in place will continue to guide GHIT through its next chapter, and I plan to stay on through the fiscal year to ensure a very smooth transition."


Hiroki Nakatani, Board Chair of GHIT says, “Dr. Slingsby’s creativity, imagination, and strong leadership have deeply influenced and catalyzed the engagement and dedication of key domestic and international stakeholders in global health for neglected patients around the globe. The paper napkin on which he first sketched GHIT’s model in 2011 is framed on the GHIT office wall. Every time our team sees it, we are reinspired and remined to keep moving forward.”